

Andrew Clark

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9415357/publications.pdf>

Version: 2024-02-01

36
papers

2,458
citations

361388

20
h-index

361001

35
g-index

37
all docs

37
docs citations

37
times ranked

4512
citing authors

#	ARTICLE	IF	CITATIONS
1	Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. <i>The Lancet Global Health</i> , 2020, 8, e1003-e1017.	6.3	760
2	Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data. <i>Lancet, The</i> , 2009, 373, 1543-1549.	13.7	290
3	Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefit–risk analysis of health benefits versus excess risk of SARS-CoV-2 infection. <i>The Lancet Global Health</i> , 2020, 8, e1264-e1272.	6.3	265
4	Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. <i>Lancet, The</i> , 2021, 397, 398-408.	13.7	144
5	Estimated economic impact of vaccinations in 73 low- and middle-income countries, 2001–2020. <i>Bulletin of the World Health Organization</i> , 2017, 95, 629-638.	3.3	109
6	Estimating global, regional and national rotavirus deaths in children aged ≤ 5 years: Current approaches, new analyses and proposed improvements. <i>PLoS ONE</i> , 2017, 12, e0183392.	2.5	103
7	Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials. <i>Lancet Infectious Diseases, The</i> , 2019, 19, 717-727.	9.1	81
8	The Equity Impact Vaccines May Have On Averting Deaths And Medical Impoverishment In Developing Countries. <i>Health Affairs</i> , 2018, 37, 316-324.	5.2	57
9	TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination. <i>Vaccine</i> , 2013, 31, C19-C29.	3.8	50
10	The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 138, 47-56.	2.3	50
11	Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. <i>ELife</i> , 2021, 10, .	6.0	50
12	Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules. <i>The Lancet Global Health</i> , 2019, 7, e1541-e1552.	6.3	46
13	Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study. <i>The Lancet Global Health</i> , 2019, 7, e1664-e1674.	6.3	44
14	Impact and cost-effectiveness of rotavirus vaccination in Bangladesh. <i>Vaccine</i> , 2017, 35, 3982-3987.	3.8	39
15	Guidelines for multi-model comparisons of the impact of infectious disease interventions. <i>BMC Medicine</i> , 2019, 17, 163.	5.5	39
16	Global Review of the Age Distribution of Rotavirus Disease in Children Aged ≤ 5 Years Before the Introduction of Rotavirus Vaccination. <i>Clinical Infectious Diseases</i> , 2019, 69, 1071-1078.	5.8	38
17	Potential effect of age of BCG vaccination on global paediatric tuberculosis mortality: a modelling study. <i>The Lancet Global Health</i> , 2019, 7, e1655-e1663.	6.3	31
18	Re-evaluating the cost and cost-effectiveness of rotavirus vaccination in Bangladesh, Ghana, and Malawi: A comparison of three rotavirus vaccines. <i>Vaccine</i> , 2018, 36, 7472-7478.	3.8	30

#	ARTICLE	IF	CITATIONS
19	Cost of illness for childhood diarrhea in low- and middle-income countries: a systematic review of evidence and modelled estimates. <i>BMC Public Health</i> , 2020, 20, 619.	2.9	29
20	Resources Required for Cervical Cancer Prevention in Low- and Middle-Income Countries. <i>PLoS ONE</i> , 2016, 11, e0164000.	2.5	29
21	Poverty reduction and equity benefits of introducing or scaling up measles, rotavirus and pneumococcal vaccines in low-income and middle-income countries: a modelling study. <i>BMJ Global Health</i> , 2018, 3, e000613.	4.7	21
22	Introduction of rotavirus vaccination in Palestine: An evaluation of the costs, impact, and cost-effectiveness of ROTARIX and ROTAVAC. <i>PLoS ONE</i> , 2020, 15, e0228506.	2.5	17
23	Evaluating the potential economic and health impact of rotavirus vaccination in 63 middle-income countries not eligible for Gavi funding: a modelling study. <i>The Lancet Global Health</i> , 2021, 9, e942-e956.	6.3	17
24	Potential impact and cost-effectiveness of rotavirus vaccination in Afghanistan. <i>Vaccine</i> , 2018, 36, 7769-7774.	3.8	16
25	Potential health impact and cost-effectiveness of bivalent human papillomavirus (HPV) vaccination in Afghanistan. <i>Vaccine</i> , 2020, 38, 1352-1362.	3.8	16
26	Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study. <i>Vaccine</i> , 2019, 37, 4987-4995.	3.8	12
27	The projected cost-effectiveness and budget impact of HPV vaccine introduction in Ghana. <i>Vaccine</i> , 2022, 40, A85-A93.	3.8	12
28	Health impact of delayed implementation of cervical cancer screening programs in India: A modeling analysis. <i>International Journal of Cancer</i> , 2019, 144, 687-696.	5.1	11
29	Projected impact, cost-effectiveness, and budget implications of rotavirus vaccination in Mongolia. <i>Vaccine</i> , 2019, 37, 798-807.	3.8	11
30	Direct and indirect costs of acute diarrhea in children under five years of age in Indonesia: Health facilities and community survey. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 19, 100333.	2.9	10
31	Potential impact and cost-effectiveness of injectable next-generation rotavirus vaccines in 137 LMICs: a modelling study. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	3.3	10
32	Cost-effectiveness analysis for rotavirus vaccine decision-making: How can we best inform evolving and complex choices in vaccine product selection?. <i>Vaccine</i> , 2020, 38, 1277-1279.	3.8	9
33	Cost-effectiveness of rotavirus vaccination in the Philippines: A modeling study. <i>Vaccine</i> , 2021, 39, 7091-7100.	3.8	6
34	Cost-effectiveness of introducing a domestic pneumococcal conjugate vaccine (PCV7-TT) into the Cuban national immunization programme. <i>International Journal of Infectious Diseases</i> , 2020, 97, 182-189.	3.3	3
35	Economic evaluation of the introduction of rotavirus vaccine in Hong Kong. <i>Vaccine</i> , 2021, 39, 45-58.	3.8	3
36	COVID-19's lost generation of unvaccinated children – Authors' reply. <i>The Lancet Global Health</i> , 2021, 9, e251.	6.3	0